Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 16/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 16/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 16/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 16/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 16/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 16/20 | 0.55 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278731 | 0.97 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15576935 | 0.95 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12379837 | 0.95 | CNR2 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23772349 | 0.92 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27943816 | 0.92 | CNR2 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15747208 | 0.90 | CNR2 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL278836 | 0.89 | TP53 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL551644 | 0.89 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9905344 | 0.89 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9976723 | 0.89 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9184391-B2 | Compound having indolocarbazole moiety and divalent linkage | XEROX CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140148567-A1 | COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | XEROX CORPORATION (US) | 2014-05-29 | — | — | US | disclosed |
| US-8673959-B2 | Polymer having indolocarbazole moiety and divalent linkage | XEROX CORPORATION (US) | 2014-03-18 | — | — | US | disclosed |
| US-8003807-B2 | organic thin film transistor with a semiconductor layer including the small molecule having didodecylindolo[3,2-b]carbazole groups | XEROX CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-7868186-B2 | Device containing polymer having indolocarbazole- repeat unit and divalent linkage | XEROX CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7829727-B2 | Device containing compound having indolocarbazole moiety and divalent linkage | XEROX CORPORATION (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100230670-A1 | DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | XEROX CORPORATION (US) | 2010-09-16 | — | — | US | disclosed |
| US-20090114909-A1 | organic thin film transistor with a semiconductor layer including the polymer of 2,8-Bis(2-thienyl)-5,11-didodecylindolo[3,2-b]carbazole; organic photovoltaics | XEROX CORPORATION (US) | 2009-05-07 | — | — | US | disclosed |
| US-7528261-B2 | Small molecule compound having indolocarbazole moiety and divalent linkage | XEROX CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080207917-A1 | POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | XEROX CORPORATION (US) | 2008-08-28 | — | — | US | disclosed |
| US-7396852-B2 | Compound having indolocarbazole moiety and divalent linkage | XEROX CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080103314-A1 | SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | XEROX CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070112167-A1 | Device containing compound having indolocarbazole moiety and divalent linkage | XEROX CORPORATION | 2007-05-17 | — | — | US | disclosed |
| US-20070112172-A1 | Compound having indolocarbazole moiety and divalent linkage | XEROX CORPORATION | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112172-A1 | Compound having indolocarbazole moiety and divalent linkage | INMT, IDO2, GRIN2C | PSEN1 3411/4885PSEN2 1708/4885APH1B 4303/4885 |
| US-20080103314-A1 | SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | SLC43A1, SLC7A5, KCNN2 | PSEN1 2508/4885PSEN2 1076/4885APH1B 4145/4885 |
| US-20100230670-A1 | DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | BRD4, BICRA, INMT | PSEN1 3828/4885PSEN2 2371/4885APH1B 3589/4885 |
| US-20080207917-A1 | POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE | SGTA, MTCL3, SMC3 | PSEN1 4346/4885PSEN2 3597/4885APH1B 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.